Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

被引：33
作者：
Imran, Mohd. [1 ]
Asdaq, Syed Mohammed Basheeruddin [2 ]
Khan, Shah Alam [3 ]
Unnikrishnan Meenakshi, Dhanalekshmi [3 ]
Alamri, Abdulhakeem S. [4 ,5 ]
Alsanie, Walaa F. [4 ,5 ]
Alhomrani, Majid [4 ,5 ]
Mohzari, Yahya [6 ]
Alrashed, Ahmed [7 ]
AlMotairi, Mohammed [8 ]
Alkhaldi, Eman H. [9 ]
Alorabi, Abeer K. [10 ]
Alshrari, Ahmed Subeh [11 ]
Tauseef, Mohammad [12 ]
Abida [1 ]
Alaqel, Saleh I. [1 ]
Alam, Ozair [13 ]
Bakht, Md. Afroz [14 ]
机构：
[1] Northern Border Univ, Dept Pharmaceut Chem, Fac Pharm, Ar Ar 91911, Saudi Arabia
[2] AlMaarefa Univ, Dept Pharm Practice, Coll Pharm, Riyadh 13713, Saudi Arabia
[3] Natl Univ Sci & Technol, Coll Pharm, Muscat 130, Oman
[4] Taif Univ, Fac Appl Med Sci, Dept Clin Lab Sci, At Taif 21944, Saudi Arabia
[5] Taif Univ, Ctr Biomed Sci Res CBSR, Deanship Sci Res, At Taif 21944, Saudi Arabia
[6] King Saud Med City, Dept Clin Pharm, Riyadh 12746, Saudi Arabia
[7] Main Hosp, Inpatient Dept, Pharmaceut Serv Adm, King Fahad Med City, Riyadh 11564, Saudi Arabia
[8] King Fahad Med City, Dept Clin Pharm, Riyadh 11564, Saudi Arabia
[9] King Saud Med City, Pharmaceut Care Serv, Riyadh 12746, Saudi Arabia
[10] King Salman Specialist Hosp, Pharmaceut Care Serv, Hail 55471, Saudi Arabia
[11] Northern Border Univ, Dept Biol Sci, Fac Sci, Ar Ar 91431, Saudi Arabia
[12] Chicago States Univ, Dept Pharmaceut Sci, Coll Pharm, Chicago, IL 60607 USA
[13] Jamia Hamdard, Dept Pharmaceut Chem, Med Chem & Mol Modelling Lab, Sch Pharmaceut Educ & Res, New Delhi 110062, India
[14] Prince Sattam Bin Abdulaziz Univ, Dept Chem, Coll Sci & Humanities, Al Kharj 11942, Saudi Arabia
来源：
PHARMACEUTICALS | 2021年 / 14卷 / 08期
关键词：
protein kinase inhibitors; USFDA; cancer; inflammation; patent review; generic product; CELL LUNG-CANCER; PRECLINICAL DEVELOPMENT; DESIGN; PLACE; DRUG; OPPORTUNITIES; PERSPECTIVES; MUTATIONS; EFFICACY; SAFETY;
D O I：
10.3390/ph14080710
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the PKIs are employed to treat cancer and inflammatory diseases. Imatinib was the first PKI approved by USFDA in 2001. This review summarizes the compound patents and the essential polymorph patents of the PKIs approved by the USFDA from 2001 to 31 May 2021. The dates on the generic drug availability of the PKIs in the USA market have also been forecasted. It is expected that 19 and 48 PKIs will be genericized by 2025 and 2030, respectively, due to their compound patent expiry. This may reduce the financial toxicity associated with the existing PKIs. There are nearly 535 reported PKs. However, the USFDA approved PKIs target only about 10-15% of the total said PKs. As a result, there are still a large number of unexplored PKs. As the field advances during the next 20 years, one can anticipate that PKIs with many scaffolds, chemotypes, and pharmacophores will be developed.
引用
收藏
页数：59
相关论文
共 217 条
[1]  
Aay N., 2010, U.S. Pat., Patent No. 7803839
[2]  
Abe H., 2008, U.S. Patent, Patent No. [7,378,423, 7378423, 7378423B2]
[3]  
Akkari R., 2014, U.S. Patent, Patent No. [8895601B2, 8895601]
[4]   Entrectinib: First Global Approval [J].
Al-Salama, Zaina T. ;
Keam, Susan J. .
DRUGS, 2019, 79 (13) :1477-1483
[5]  
Alfons T.G., 2009, U.S. Patent, Patent No. [8877933B2, 8877933]
[6]   Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy [J].
Ali, Robert ;
Arshad, Junaid ;
Palacio, Sofia ;
Mudad, Raja .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 :569-580
[7]  
Alisha B., 2019, U.S. Patent, Patent No. [10172861B2, 10172861]
[8]  
Allian A., 2018, U.S. Patent, Patent No. [9951080B2, 9951080]
[9]  
Andrews S.W., 2015, U.S. Patent, Patent No. [9127013B2, 9127013]
[10]  
Andrews S.W., 2018, U.S. Patent, Patent No. [10112942B2, 10112942]
12345678910